Wednesday, March 23, 2022

FDA OKs pembrolizumab for advanced endometrial cancer

FDA OKs pembrolizumab for advanced endometrial cancer

The FDA approved the use of Merck's Keytruda, or pembrolizumab, for endometrial carcinoma that has advanced despite prior treatment in patients who are not eligible for radiation or curative surgery, according to the company. The decision was based on data from the company's KEYNOTE-158 trial, which found a 46% objective response rate among participants who received Keytruda.

Full Story: PMLive (UK) (3/22) 


No comments:

Post a Comment